Clinical

New research presented at AMCP 2021, the annual meeting of the Academy of Managed Care Pharmacy, evaluated treatment patterns and costs related to hospitalization for patients with pulmonary arterial hypertension (PAH).

The CDC's Advisory Committee on Immunization Practices (ACIP) declined to change the current recommendation to pause administration of Johnson & Johnson's COVID-19 vaccine.

After cases of rare and severe blood clots led to 1 death and 1 hospitalization, the CDC and FDA will pause the use of Johnson & Johnson's (J&J) COVID-19 vaccine.

Hospital reimbursement deals slow the adoption of biosimilars in oncology, but cost concerns contribute to the incentives to use these agents.

Russell Langan, MD, chief of Surgical Oncology and Hepatopancreatobiliary Surgery at Saint Barnabas Medical Center discusses the workflow of a cloud-based data management platform for patients with pancreatic cysts.

The findings illustrate the importance of prioritizing COVID-19 vaccinations for patients on dialysis.

Patients who experienced a fall within 12 months of multiple myeloma (MM) treatment initiation had a shorter median survival compared to those without falls.

Patients who cut their calorie intake by at least 10% and exercised modestly were 70% less likely to have remaining leukemic cells in their bone marrow 1 month after starting chemotherapy, according to results of an early study.

The study also indicated that the type of transplantation donor impacted outcomes following the procedure.

More information will come from 4-year results, which will be critical to assess whether there is any long-term benefit to visual acuity using aflibercept.

Registry of patients with pulmonary arterial hypertension (PAH) treated with selexipag provides insights into real-world dosing regimens and outcomes.

Results of a retrospective cohort study show that utilization of erenumab was associated with a decreased use of acute and preventive prescription migraine medications. Although adherence to erenumab was higher than other traditional oral prophylactic migraine therapies, adherence rates can be improved.

Kathryn Gold, MD, medical oncologist and associate professor of medicine at UC San Diego, who is a member of the NCCN guidelines panel for small-cell lung cancer, gives insight into the guidelines and the importance of frequent updates.

The combination of lenalidomide with steroid dexamethasone is standard of care in multiple myeloma (MM), but new research shows older patients can be spared the steroids.

Potential biomarkers include tumor mutational burden, microsatellite instability, and circulating tumor DNA.

Behçet disease (BD), a rare systemic inflammatory disease, is associated with multiple sclerosis (MS) and rheumatoid arthritis (RA).

According to authors, magnetic resonance imaging (MRI) should be used when incomplete signs of the rare complication are presented to help guide the skin biopsy.

Classical mantle cell lymphoma (MCL) and 2 aggressive variants exhibited similar rates of negativity for the CD5 marker, but further testing may be needed in certain cases to avoid misdiagnosis with diffuse large B-cell lymphoma (DLBCL).

Multiple myeloma is the second most common blood cancer, affecting more than 130,000 US patients.

In patients with chronic inflammatory rheumatic and musculoskeletal diseases (RMD), the presence of metabolic syndrome (MetS) indicates an increased risk of cancer.

Study findings indicate that droplet digital polymerase chain reaction (ddPCR) may be more accurate than real-time quantitative PCR in measuring minimal residual disease (MRD) among pediatric patients with acute lymphoblastic leukemia (ALL), particularly in late follow-up time points.

Anemia, which occurs in over 50% of patients with end-stage kidney disease, should not be considered an obstacle to home dialysis, according to a new report.

Russell Langan, MD, chief of Surgical Oncology and Hepatopancreatobiliary Surgery at Saint Barnabas Medical Center, details the implementation of the center's Pancreatic Cyst Surveillance Program.

As more therapies continue to be approved, efforts will focus on toxicity prevention and mitigation strategies for associated unique and potentially life-threatening adverse reactions.

A recent subgroup analysis of the DAPA-HF study investigated possible clinical outcome differences between women and men following the addition of dapagliflozin to their treatment regimens.